Content
Clinical-Stage BioTech Drug Stocks Portfolio Went Down 9% Last Week
Article By:
Lorimer Wilson
Read
Tuesday, April 23, 2024 12:57 PM EDT
A look at the 10 clinical-stage AI-powered and psychedelic compound-based small-cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, their stock performances last week and MTD, and their areas of focus.
Sweet Nektar?
Article By:
Tim Knight
Read
Monday, April 22, 2024 1:40 PM EDT
NKTR has had a terrible time of it for years, but maybe it’s finally ready to turn around.
In this article: NKTR
The 10 Stocks In The Clinical-Stage BioTech Drug Stocks Index Are Down 4% YTD
Article By:
Lorimer Wilson
Read
Monday, April 15, 2024 6:45 AM EDT
The pharmaceutical industry is embracing AI to streamline drug discovery and researching the use of psychedelic compound-based ingredients for the treatment of, as yet, untreatable diseases.
Alvotech's Share Price At A Critical Juncture
Article By:
Hallsteinn Arnarson
Read
Saturday, April 13, 2024 7:50 PM EDT
Insights into the largest company, market-cap-wise, on the Iceland market.
Viking Therapeutics: Strong Results In Obesity
Article By:
MoneyShow.com
Read
Saturday, April 13, 2024 5:17 PM EDT
With a potential best in class drug for oral and injectable use, Viking Therapeutics has to be on many Big Pharma/Bio acquisition wish lists, as the company represents a very scarce asset in the $100 billion market for weight loss drugs.
MicroMarvel - Atossa Therapeutics
Article By:
Jim Van Meerten
Read
Saturday, April 6, 2024 7:49 PM EDT
Atossa Therapeutics, a biopharmaceutical company focused on developing medicines in oncology, has a lead program in Phase II clinical trials for breast cancer, and 100% technical buy signals
In this article: ATOS
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
Article By:
ChinaBio® Today
Read
Saturday, April 6, 2024 1:20 PM EDT
ProfoundBio will be acquired by Copenhagen’s Genmab A/S in a $1.8 billion all-cash deal. The acquisition will expand Genmab’s drug portfolio, including three ProfoundBio clinical stage ADC candidates for solid tumors.
Tuesday Talk: April Is The Cruelest Month?
Article By:
David Marshall
Read
Tuesday, April 2, 2024 8:25 AM EDT
At least that is what the poet T.S. Eliot wrote in the opening line of his well-known poem, "The Wasteland". With all the chatter about an April correction it might be, but traditionally April is one of the strongest months for the stock market.
Healthcare And Biotech Stocks Review: Q1 2024 Performance
Article By:
Rod Raynovich
Read
Monday, April 1, 2024 4:07 AM EDT
We just had one of the best first quarters in recent market history since Q1 in 2019 when the market was up 13%. But changes in sector performance may be coming. The S&P 500 was up 10% showing a slight trend toward more balanced performance.
2 Top Biotech Buyout Candidates
Article By:
Andrew Rocco
Read
Sunday, March 31, 2024 4:00 PM EDT
Investors who are adventurous, have a high-risk tolerance, and are home run hitters may opt for biotech stocks. Investors in this group may want to hone in on stocks that have the potential to be bought out. Here are some top buyout candidates.
Week In Review: AriBio Sells China Rights To Alzheimer’s Candidate In $770 Million Deal
Article By:
ChinaBio® Today
Read
Saturday, March 30, 2024 2:40 PM EDT
South Korea’s AriBio out-licensed China rights for AR1001, an Alzheimer’s disease candidate, in an agreement worth up to $770 million. The company acquiring the asset asked to remain anonymous because of the competition for Alzheimer’s drugs.
These DAX Index Stocks Surged In The First Quarter
Article By:
Invezz
Read
Thursday, March 28, 2024 5:56 AM EDT
The DAX index had a great performance in the first quarter of the year as global stocks roared back. It soared by more than 26% this year, reaching a record high of €18,477. Most recently, the index has risen in the past eight straight weeks.
In this article: DAX
Tuesday Talk: Big-Tech Under Attack
Article By:
David Marshall
Read
Tuesday, March 26, 2024 5:20 AM EDT
On Thursday the Justice Dept. filed an antitrust suit against Apple. The suit joins two others already filed against Google. How much this will affect the market in the long run is up for grabs.